{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:26:27Z","timestamp":1783193187109,"version":"3.54.6"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the role of pretreatment neutrophil\u2010to\u2010lymphocyte ratio (NLR) and platelet\u2010to\u2010lymphocyte ratio (PLR) in the prediction of response to sequential intravesical therapy, gemcitabine and docetaxel (Gem\/Doce), given to patients with bacille Calmette\u2013Gu\u00e9rin (BCG)\u2010 na\u00efve high\u2010risk non\u2010muscle\u2010invasive bladder cancer (NMIBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was conducted on 115 patients who received intravesical Gem\/Doce for high\u2010risk NMIBC between January 2011 and December 2021. Data were computed as the median (interquartile range [IQR]) or mean (standard deviation [\n                      <jats:sc>sd<\/jats:sc>\n                      ]). Cox regression analysis was performed to determine if neutrophilia, NLR, platelet counts, and PLR before instillation therapy were predictive of recurrence\u2010free survival (RFS) and overall survival (OS). Predictive performance was estimated using Uno's C\u2010statistic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median (IQR) follow\u2010up for the overall cohort was 23\u2009(13\u201336)\u2009months. The mean (\n                      <jats:sc>sd<\/jats:sc>\n                      ) values for NLR, PLR and platelet counts were 3.4\u2009(2.3), 142.2\u2009(85.5), and 225.2\u2009(75.1)\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L, respectively. NLR was associated with RFS, with a hazard ratio of 1.32 (95% confidence interval CI 1.19\u20131.46). Concordance analysis showed that NLR had a good ability to predict RFS (C\u2010index: 0.7,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). The PLR and platelet count were not associated with RFS and did not predict recurrence. In terms of OS, none of these cellular inflammatory markers showed any prediction value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre\u2010treatment NLR provides some predictive accuracy for RFS in high\u2010risk BCG\u2010na\u00efve patients receiving Gem\/Doce. Further prospective trials are needed to validate this finding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.16486","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T06:18:17Z","timestamp":1722406697000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic role of the neutrophil\/lymphocyte ratio in high\u2010risk BCG\u2010na\u00efve non\u2010muscle\u2010invasive bladder cancer treated with intravesical gemcitabine\/docetaxel"],"prefix":"10.1111","volume":"135","author":[{"given":"Mohamad Abou","family":"Chakra","sequence":"first","affiliation":[{"name":"Department of Urology University of Iowa Hospitals and Clinics  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-3094","authenticated-orcid":false,"given":"Riitta","family":"Lassila","sequence":"additional","affiliation":[{"name":"Unit of Coagulation Disorders, Department of Hematology Helsinki University Central Hospital  Helsinki Finland"},{"name":"Research Program Unit in Systems Oncology, Faculty of Medicine University of Helsinki  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-5069","authenticated-orcid":false,"given":"Nancy","family":"El Beayni","sequence":"additional","affiliation":[{"name":"Unit of Coagulation Disorders, Department of Hematology Helsinki University Central Hospital  Helsinki Finland"},{"name":"Department of Pathology and Laboratory Medicine American University of Beirut Medical Center  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Mott","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center University of Iowa  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-6427","authenticated-orcid":false,"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology University of Iowa Hospitals and Clinics  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.028"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.06.011"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.372"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-59038-3_17"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.5301\/uro.5000031"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2018.0249"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00642"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2015.0243"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.907485"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.05.013"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.03.007"},{"key":"e_1_2_9_15_1","first-page":"281","article-title":"Prognostic significance of the neutrophil\u2010to\u2010lymphocyte ratio in patients with non\u2010muscle invasive bladder cancer treated with intravesical bacillus Calmette\u2010Gu\u00e9rin and the relationship with the CUETO scoring model","volume":"19","author":"Chung JW","year":"2021","journal-title":"Urol J"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.06.006"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.10.030"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000688"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.983082"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827457"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000300"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01270"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-009-9195-6"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/983698"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-35723-8_1"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171065"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8345286"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2018.05.010"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2022.11.06"},{"key":"e_1_2_9_31_1","volume-title":"StatPearls","author":"Amjad MT","year":"2023"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.16486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:40:55Z","timestamp":1761734455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.16486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/bju.16486"],"URL":"https:\/\/doi.org\/10.1111\/bju.16486","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"2024-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}